Theriva Biologics, Inc. (TOVX)

Compare

1.1800

0.0000

(0.00%)

At close: April 3 at 4:00:00 PM EDT

1.1800

0.00

(0.00%)

After hours: April 3 at 5:30:02 PM EDT

Theriva™ Biologics Announces Positive Outcomes from the Second Meeting of the Independent Data Monitoring Committee for VIRAGE, the Company’s Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

The independent data monitoring committee (IDMC) considered VCN-01 to be well tolerated in metastatic PDAC patients treated with standard-of-care chemotherapy gemcitabine/nab-paclitaxelROCKVILLE, Md., March 31, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that a second Independent Data Monitoring Committee (IDMC) review of d

GlobeNewswire 3 days ago

TOVX
0.00%
Theriva™ Biologics to Present at the 2025 NeauxCancer Conference

ROCKVILLE, Md., March 19, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that the Company’s Management will be attending and presenting at the Cancer Advocacy Group of Louisiana (CAGLA) NeauxCancer 2025 Conference being held March 27th-29th, 2025 at The Roosevelt New Orleans Hotel in New Orleans, LA. A company presentation wil

GlobeNewswire 15 days ago

TOVX
0.00%
Q1 Virtual Investor Summit: On-Demand Presentations Now Live

NEW YORK, NY / ACCESS Newswire / March 18, 2025 /The Investor Summit is excited to announce that presentations from Q1 Investor Summit are now available for on-demand viewing. Attendees and investors who missed the live sessions can now access company ...

ACCESS Newswire 16 days ago

VOXR

PYPD

GIFT
Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results

– Enrollment completed in VIRAGE Phase 2b clinical trial of VCN-01 in metastatic pancreatic ductal adenocarcinoma (PDAC); topline data expected in Q2 2025 – – VCN-01 development bolstered by FDA award of Fast Track designation for the treatment of PDAC and Rare Pediatric Disease designation for retinoblastoma – – Received guidance from the FDA and EMA on Phase 3 pivotal trial design for VCN-01 in combination with standard-of-care chemotherapy for metastatic PDAC – –– As of December 31, 2024, The

GlobeNewswire 28 days ago

TOVX
0.00%
Theriva™ Biologics to Participate in the Q1 Investor Summit Virtual

ROCKVILLE, Md., March 05, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that Steve Shallcross, Chief Executive Officer, and Manel Cascallo, PhD., General Director will present at the Q1 Investor Summit Virtual. Theriva’s management team will participate in 1x1 meetings. Q1 Investor Summit VirtualFormat: PresentationPresenter:

GlobeNewswire 29 days ago

TOVX
0.00%
Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer

ROCKVILLE, Md., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the outcomes of a recent Type D meeting with the U.S. Food and Drug Administration (FDA) to obtain guidance on the design of a Phase 3 clinical study of lead clinical candidate VCN-01 in combination with standard-of-care chemotherapy for the treatment of m

GlobeNewswire 3 months ago

TOVX
0.00%
Theriva Biologics: Q3 Earnings Snapshot

ROCKVILLE, Md. AP) — Theriva Biologics, Inc. TOVX) on Tuesday reported a loss of $7.7 million in its third quarter.

Associated Press Finance 4 months ago

TOVX
0.00%
Theriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech Grant

Winner to be Presented at BIO-Europe 2024 in Stockholm, SwedenROCKVILLE, Md., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced selection as one of five finalists for Merck KGaA's EMEA Advance Biotech Grant. Finalists for the grant will present to a six-judge panel from Merck’s Emerging Biotech group during BIO Europe 20

GlobeNewswire 4 months ago

TOVX
0.00%
Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma

ROCKVILLE, Md., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that the European Commission has adopted the European Medicines Agency (EMA) recommendation to grant orphan medicinal product designation to lead clinical candidate VCN-01, Theriva’s systemic, selective, stroma-degrading oncolytic adenovir

GlobeNewswire 5 months ago

TOVX
0.00%
Nano-Cap Theriva Biologics' Investigational Drug For Transplant-Related Complication Shows Safety In Bone Marrow Transplant Patients

On Thursday, Theriva Biologics, Inc. (NYSE:TOVX) revealed the outcome of the Data and Safety Monitoring Committee (DSMC) review of results from the second cohort of its Phase 1b/2a trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant (HCT) recipients to prevent acute graft-versus-host disease (aGVHD). Allogeneic hematopoietic cell transplant is a type of bone marrow transplant. GVHD is a common complication when transplanted donor cells recognize the recipient’s tissues as f

Benzinga 5 months ago

TOVX
0.00%
Theriva™ Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

DSMC has reviewed the safety and pharmacokinetic data from Cohort 2 and recommended that the study proceed to enroll patients into Cohort 3ROCKVILLE, Md., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced a positive outcome from the Data and Safety Monitoring Committee (DSMC) review of

GlobeNewswire 5 months ago

TOVX
0.00%
Theriva Biologics Announces Pricing of $2.5 Million Public Offering

ROCKVILLE, Md., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE American: TOVX) (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the pricing of its “reasonable best efforts” public offering for the purchase and sale of up to 1,428,600 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 1,428,600 shares of

GlobeNewswire 6 months ago

TOVX
0.00%
Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

- Target of 92 evaluable patients (46 in each of the control and VCN-01 treatment arms) enrolled across 15 sites in Spain and the USA within 21 months – ROCKVILLE, Md., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that it has achieved their target patient enrollment in the VIRAGE

GlobeNewswire 6 months ago

TOVX
0.00%
Theriva™ Biologics Awarded Manufacturing Funding from the Spanish Government’s National Knowledge Transfer Program

Theriva Biologics and the Universitat Autònoma de Barcelona to receive a total of €2.28 Million to support the THERICEL project, a suspension cell platform for manufacturing viral-based therapiesROCKVILLE, Md., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”) a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that the THERICEL project has b

GlobeNewswire 6 months ago

TOVX
0.00%
Upcoming Stock Splits This Week (August 26 to August 30) – Stay Invested

These are the upcoming stock splits for the week of August 26 to August 30, based on TipRanks’ Stock Splits Calendar. A stock split is a corporate action in which the company issues additional common shares to increase the number of outstanding shares. Accordingly, the stock price of the company’s shares decreases, which maintains the market capitalization before and after the split. In contrast, there are also reverse stock splits that reduce the number of outstanding shares (consolidate). In t

TipRanks 7 months ago

FBRX

GDEV

GDEVW
Theriva Biologics Announces Reverse Stock Split

ROCKVILLE, Md., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, announced today a reverse stock split of its issued and outstanding common stock, par value $0.001 per share, at a ratio of one (1) share of common stock for every twenty five (25) shares of common stock, effective as of 12:01 a.m. (Eastern Time) on August 26, 2024 (the “Effective Date

GlobeNewswire 7 months ago

TOVX
0.00%
Theriva Biologics: Q2 Earnings Snapshot

ROCKVILLE, Md. AP) — Theriva Biologics, Inc. TOVX) on Tuesday reported a loss of $8.3 million in its second quarter.

Associated Press Finance 7 months ago

TOVX
0.00%
Theriva™ Biologics Reports Second Quarter 2024 Operational Highlights and Financial Results

- VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma (PDAC), is expected to complete enrollment in the third quarter of 2024- - Received Fast Track Designation (FTD) Granted by the U.S. Food and Drug Administration (FDA) for VCN-01 for the treatment of metastatic pancreatic adenocarcinoma- - Received Rare Pediatric Disease Designation (RPDD) Granted by the U.S. Food and Drug Administration (FDA) for VCN-01 for the treatm

GlobeNewswire 7 months ago

TOVX
0.00%
Theriva™ Biologics Receives Rare Pediatric Drug Designation by the U.S. FDA for VCN-01 for the Treatment of Retinoblastoma

ROCKVILLE, Md., July 31, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Drug Designation (RPDD) for VCN-01 for the treatment of retinoblastoma. VCN-01, Theriva’s lead product candidate, is a systemic, selective, stroma-degrading oncolytic adenovirus.

GlobeNewswire 7 months ago

TOVX
0.00%
Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer

ROCKVILLE, Md., May 23, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to lead clinical candidate VCN-01 in combination with gemcitabine and nab-paclitaxel to improve progression-free survival and overall survival in patients with metasta

GlobeNewswire 10 months ago

TOVX
0.00%

Performance Overview

Return	TOVX	S&P 500 (^GSPC)
YTD	-32.57%	-8.25%
1-Year	-89.51%	+3.55%
3-Year	-98.37%	+18.71%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Theriva Biologics, Inc. (TOVX)

Theriva™ Biologics Announces Positive Outcomes from the Second Meeting of the Independent Data Monitoring Committee for VIRAGE, the Company’s Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Theriva™ Biologics to Present at the 2025 NeauxCancer Conference

Q1 Virtual Investor Summit: On-Demand Presentations Now Live

Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results

Theriva™ Biologics to Participate in the Q1 Investor Summit Virtual

Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer

Theriva Biologics: Q3 Earnings Snapshot

Theriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech Grant

Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma

Nano-Cap Theriva Biologics' Investigational Drug For Transplant-Related Complication Shows Safety In Bone Marrow Transplant Patients

Theriva™ Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Theriva Biologics Announces Pricing of $2.5 Million Public Offering

Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

Theriva™ Biologics Awarded Manufacturing Funding from the Spanish Government’s National Knowledge Transfer Program

Upcoming Stock Splits This Week (August 26 to August 30) – Stay Invested

Theriva Biologics Announces Reverse Stock Split

Theriva Biologics: Q2 Earnings Snapshot

Theriva™ Biologics Reports Second Quarter 2024 Operational Highlights and Financial Results

Theriva™ Biologics Receives Rare Pediatric Drug Designation by the U.S. FDA for VCN-01 for the Treatment of Retinoblastoma

Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer

Performance Overview